Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Aethlon Medical (AEMD) Long-Term Debt Repayments (2019)

Aethlon Medical filings provide 6 years of Long-Term Debt Repayments readings, the most recent being $892591.0 for Q3 2019.

On a quarterly basis, Long-Term Debt Repayments changed N/A to $892591.0 in Q3 2019 year-over-year; TTM through Jun 2020 was $892591.0, a 792.59% increase, with the full-year FY2020 number at $992591.0, changed N/A from a year prior.
Long-Term Debt Repayments hit $892591.0 in Q3 2019 for Aethlon Medical, up from $100000.0 in the prior quarter.
In the past five years, Long-Term Debt Repayments ranged from a high of $892591.0 in Q3 2019 to a low of $22502.0 in Q1 2015.